Biocompatibility and Surface Characteristics of Resin-Modified Glass Ionomer Cements with Ammonium Quaternary Compounds or Silver Nanoparticles: An In Vitro Study

Table 3

Cell viability percentages by MTT assay for GC Fuji ORTHO LC modifications.

Groups	Mean	SD	Maximum	Minimum
MEM control	100	0	100	100
GC Fuji ORTHO LC	11.16	1.94	13.75	9.62
GC Fuji ORTHO LC + hexadecyltrimethylammonium bromide 1%	10.95	0.72	11.5	10
GC Fuji ORTHO LC + hexadecyltrimethylammonium bromide 2%	10.37	0.75	11.37	9.75
GC Fuji ORTHO LC + benzalkonium chloride 1%	11.25	0	11.25	11.25
GC Fuji ORTHO LC + benzalkonium chloride 2%	9.41	0.488	10	8.87
GC Fuji ORTHO LC + cetylpyridinium chloride 1%	9.66	1.19	11.25	8.75
GC Fuji ORTHO LC + cetylpyridinium chloride 2%	10.62	0.49	11.12	10
GC Fuji ORTHO LC + silver nanoparticles 1%	10.83	1.65	12.5	8.75
GC Fuji ORTHO LC + silver nanoparticles 2%	11.95	0.43	12.5	11.5

SD: standard deviation; MTT assay: 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl-tetrazolium bromide assay. Statistically significant differences between GC Fuji ORTHO LC and the experimental group.